Additional information
| Active substance | Letrozole |
|---|---|
| ean13 | 1396118393158 |
| Side effects | Hot flashes, joint pain, fatigue, risk of osteoporosis |
| Effects | Reduces estrogen levels, increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) |
| Dosage (sports) | 1.25 mg to 2.5 mg every other day |
| Dosage (medical) | 2.5 mg once daily |
| Half-life | Approximately 2 days |
| Main action | Inhibits the enzyme aromatase, which is involved in estrogen synthesis |
| Substance class | Aromatase inhibitor |
| Formula | C17H11N5 |
| Chemical name | Letrozole |
| Storage conditions | Store at room temperature away from moisture and heat |
| Tab Piece | 30 Tabs |
| Reference | SMHPAH25 |
| Dosage Unit | Tabs |
| FORM | Oral |
| Trade name | Femara |
| Blood pressure | May cause a decrease |
| Also known as | Letrozole |
| Lab Test | Monitoring of blood estrogen levels and liver function tests |
| Aromatization | No |
| Hepatotoxicity | No |
| HBR | No |
| Water Retention | No |
| Acne | No |
| Dosage | 0.5 – 2.5 mg/day |
| Classification | Non-steroidal aromatase inhibitor |
| Active Half-Life | 2 days |
| Use in sports | Used to counteract the side effects of estrogen produced by aromatizing anabolic steroids |
| Packing | Blister |
Reviews
There are no reviews yet.